Founded with a mission to enhance vascular surgery outcomes, Vascular Therapies is a biopharmaceutical company focused on improving the lives of patients with kidney and vascular diseases. The company specializes in developing innovative treatments that aim to reduce surgical stenosis and improve vascular access for hemodialysis patients. Their primary product involves the use of synthetic grafts to create arteriovenous connections, which are crucial for effective hemodialysis.
Vascular Therapies has garnered attention through its ACCESS 2 Clinical Study and has been supported by a dedicated management team and board of directors with extensive experience in the biopharmaceutical sector. The company's research and clinical advancements have significantly impacted the quality of life for patients requiring hemodialysis, positioning Vascular Therapies as a key player in the field of vascular health.
